Noticias PureTech Health PLC - PRTC | Acciones NASDAQ

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients...

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the...

PureTech Appoints UBS as UK Corporate Broker

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed UBS as its UK Corporate...

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID1) and...

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included in a planned Phase 2b study in major depressive...

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

LYT-200 is generally safe and well-tolerated as a single agent as well as in combination with standard-of-care venetoclax and hypomethylating...

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

Lead Independent Director at Microsoft and former Group Worldwide Chair for Johnson & Johnson brings extensive experience in life sciences...

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc...

PureTech to Present at Two Upcoming Investor Conferences

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the...

PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Financing led by General Atlantic with participation from other top tier investors Proceeds will support key clinical milestones in Seaport’s...

PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting

IPF patient survey provides new insights into disease burden and patient experience one decade after the approval of the first antifibrotics for...

PureTech to Present at CHEST 2024 Annual Meeting

Three presentations inform clinical, commercial and patient engagement strategies for LYT-100 for the treatment of idiopathic pulmonary fibrosis...

PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Milestone triggers payments to PureTech totaling $29 million under agreements with Royalty Pharma and PureTech’s Founded Entity, Karuna...

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33ALLO demonstrates encouraging...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Number sleven 1 minuto hace

https://www.courtlistener.com/docket/59859757/dr-reddys-laboratories-inc-v-amarin-pharma-inc/?page=2
Sleven,

AMRN

price_and_volume 5 minutos hace

"Right news" gonna get $175-350MM market cap? LOL!

Omg what a maroon.

VXIT

The Danish Dude 5 minutos hace

Nice and interesting analysis, but completely irrelevant >!

I fed ChatGPT the following five comments regarding this analysis and it disagrees with you.

I saw these comments regarding how MHRA approves or rejects medecines at mhra meetings

1

NWBO

lakers17 7 minutos hace

MTC back to $96,000 after hitting $89, 200s yesterday. Cryptos I added to in the last couple of days were BOBO, PAI, OTTO and CLUSTR. RING AI looking better. Boom or bust for me.

MTC

Golden Cross 10 minutos hace

Loading Zone Here! $ASII

ASII

Hi_Lo 19 minutos hace

Where is the CSE press release filing?

TWOH has been halted for more than a week now and the CSE press release is still missing.

Could the run up before the halt be the problem?

Could some people have been tipped off before the run up?

Coul

TWOH

SkeBallLarry 26 minutos hace

https://scontent-mia3-1.xx.fbcdn.net/v/t39.30808-6/473323273_992397186268896_4170433101098362110_n.jpg?_nc_cat=100&ccb=1-7&_nc_sid=833d8c&_nc_ohc=UebR9WKXEXsQ7kNvgELlMGV&_nc_zt=23&_nc_ht=scontent-mia3-1.xx&_nc_gid=AvB9U-Cb1bfWGguzkXzMzar&oh=00_AYDqG-tA0ScuUz90hSjz11X1LQL5aezyuhOfdBXmp9pGuQ&oe=678C04

Dodger1 28 minutos hace

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175652942 I Miss Real

AABB

jondoeuk 31 minutos hace

NEUK201-00* is being tested in advanced/metastatic solid tumours at a single site.

https://i.postimg.cc/fyWcxcwj/download.png

* It could be an iNK with just a high-affinity non-cleavable CD16(a) receptor, but this comes from a Chinese site that has under

HPQ

marcis 32 minutos hace

I was just thinking the same thing

Go bother those serial OTC stock hijackers
( we know them all well ) that’s been doing LOI mergers, asset ( no asset ) transfers for years with never a real company.
( not you Prophet, to the shills )
Save those investors

RDAR

No-Quarter 33 minutos hace

Good to know, thx!

LetGoodTimesRoll 33 minutos hace

The criminality surrounding BLUE Sheets data is rampant...

https://www.sec.gov/newsroom/press-releases/2025-5?utm_medium=email&utm_source=govdelivery

FOXO

Seminole Red 34 minutos hace

https://scontent-mia3-2.xx.fbcdn.net/v/t39.30808-6/472742874_1004087688423643_1614366062036311373_n.jpg?_nc_cat=1&ccb=1-7&_nc_sid=833d8c&_nc_ohc=nfcGrMsEIhAQ7kNvgF3nw1U&_nc_zt=23&_nc_ht=scontent-mia3-2.xx&_nc_gid=AZgGdnGS_3zIT8EnJ2PY5KX&oh=00_AYA_PYWQyRmy2OxdvryhKxL8uHQSf69FZtEDZ_CZJ06VFQ&oe=678BF3D

Bubae 34 minutos hace

New shares flying everywhere from the looks of the filings. Form 144 filed on January 10th by Atlas Merchant Capital LLC intent to sell 1,241,144 shares. approximate date of sale listed as 01/10/2025. Robert E. Diamond, Triller Chairman of the Board, Chief Executive Officer of Atlas Merchant Capita

ILLR

meshcan 36 minutos hace

Yes, hence I was saying the really numbers will be in a couple quarters from now, August CC will be two full quarters that we have Vyvanse sell numbers.

CC: NASDAC2020

ELTP

PlaneReflection 36 minutos hace

Remember when you said it won't pass $2 again?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174119656

Please say it won't pass $10 again, $30 again and it'll never be over $200. Thanks.

FNMA

eagle8 38 minutos hace

ATLnsider
@ATLnsider
Global future for $NWBO #DCVax dendritic cell vaccine platform could be unlimited if efficacy is proven to be tumor & tissue agnostic for all solid tumor cancers & when combined with checkpoint inhibitors can also effectively treat all blood or liquid cancers. NWBi

NWBO

PROPHET-of-PROFITS 38 minutos hace

The old CEO of rdar has a new stock already to transfer all of his garbage into. But you watch the bearish comments here Will Never follow Jacob to that new stock where efforts should be made to protect people from making a bad investment. Negative bearish comments and all the effort to create them

RDAR

Pickme2 39 minutos hace

The only proof here is you constantly saying this is the best setup and challenge...yet it keeps going down down from .31 cents to .03 ...now .05 and despite the company saying this S-1 offering filled with the SEC will cause dilution and shareholders will have a hard time selling...you continue to

ATMH

PC retired 41 minutos hace

Yes, it has gone deathly quiet. I have little to say other than wishing you, Richard H2, a happy and prosperous new year.

ASRE

eagle8 42 minutos hace

Someone without a name wrote this ;)

➡️MTD Timeline: More Speculation⬅️

For all of those, including myself, (im)patiently waiting for $NWBO's spoofing case Motion to Dismiss (MTD) decision, I've done a deep dive into Magistrate Judge Stein's Report and Recommendation (R

NWBO

marcis 45 minutos hace

Agree
The deep experience management team is on this
And with $45 million working capital

Buckle up

RDAR

marcis 49 minutos hace

It’s my opinion that, JanBelle Capital or an associate fund, was the short buyer of $100k one big size trade at the high of the day .002 Dec 06

I think that the short position, if I’m correct, is about finished after making a cool $80,00” - $90,000 minus fees for the month

RDAR

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

PureTech Health PLC (PRTC)

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

PRTC Noticias

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Appoints UBS as UK Corporate Broker

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech to Present at Two Upcoming Investor Conferences

PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting

PureTech to Present at CHEST 2024 Annual Meeting

PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Discusión

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

PureTech Health PLC (PRTC) Noticias

PureTech Health PLC (PRTC)

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

PRTC Noticias

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Appoints UBS as UK Corporate Broker

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech to Present at Two Upcoming Investor Conferences

PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting

PureTech to Present at CHEST 2024 Annual Meeting

PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Discusión

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación